{
  "meta": {
    "title": "91_Platelet_Disorders",
    "url": "https://brainandscalpel.vercel.app/91-platelet-disorders-ef6a9298.html",
    "scrapedAt": "2025-11-30T12:29:17.654Z"
  },
  "questions": [
    {
      "text": "What is the lifespan of a platelet?",
      "choices": [
        {
          "id": 1,
          "text": "24 hours"
        },
        {
          "id": 2,
          "text": "5 days"
        },
        {
          "id": 3,
          "text": "7 days"
        },
        {
          "id": 4,
          "text": "2 weeks"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The average <strong>lifespan</strong> of <strong>platelets</strong> in circulation is <strong>7&ndash;10 days</strong>.</p>\n<p>Thrombopoietin <strong>(TPO)</strong> is the regulator of platelet production. A reduction in platelet and megakaryocyte mass increases the level of TPO, which then stimulates platelet production.</p>\n<p>The shelf life of donor platelets is 5 days. It is stored on a special agitator at 20-24 &deg;C.&nbsp;The half-life of transfused platelets is 3-5 days.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1457",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following would you not expect to see in patients with a platelet disorder?",
      "choices": [
        {
          "id": 1,
          "text": "Petechiae"
        },
        {
          "id": 2,
          "text": "Ecchymosis"
        },
        {
          "id": 3,
          "text": "Hemarthrosis"
        },
        {
          "id": 4,
          "text": "Gastrointestinal bleeds"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Hemarthrosis</strong> is highly suggestive of a <strong>coagulation disorder,&nbsp;</strong>not a platelet disorder.</p>\n<p>Bleeding diathesis can occur due to:</p>\n<ul>\n<li>Platelet disorders - mucocutaneous bleeding like <strong>petechiae</strong>, purpura, <strong>ecchymoses</strong>, epistaxis, menorrhagia, gastrointestinal (<strong>GI</strong>) <strong>bleeds</strong></li>\n<li>Coagulation disorders - hemarthrosis, muscle hematomas, and bleeding into soft tissues</li>\n<li>Disorders of the vessel wall (Henoch-Sch&ouml;nlein purpura, scurvy) - purpura and ecchymosis&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/98bceb172651412e82d9eab512b76b04x1280x2210.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Differences between Bleeding Disorders and Coagulation disorders</h3><table>\n<tbody>\n<tr>\n<td><strong>Finding</strong></td>\n<td><strong>Bleeding disorders</strong></td>\n<td><strong>Coagulation disorders</strong></td>\n</tr>\n<tr>\n<td>Cause</td>\n<td>\n<p>Quantitative/ Qualitative platelet abnormality</p>\n</td>\n<td>Deficiency of clotting factors</td>\n</tr>\n<tr>\n<td>Sex</td>\n<td>More common in females (commonly autoimmune)</td>\n<td>More common in males (commonly X-linked)</td>\n</tr>\n<tr>\n<td>Family history</td>\n<td>Rare (except in VWD)</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Petechiae</td>\n<td>Characteristic</td>\n<td>&nbsp;Rare</td>\n</tr>\n<tr>\n<td>Superficial ecchymosis</td>\n<td>Small and Multiple</td>\n<td>Large and Solitary</td>\n</tr>\n<tr>\n<td>Bleeding from superficial cuts&nbsp;</td>\n<td>Profuse</td>\n<td>Minimal persistent</td>\n</tr>\n<tr>\n<td>Hemarthrosis</td>\n<td>Rare</td>\n<td>Characteristic (most common-knee)</td>\n</tr>\n<tr>\n<td>Deep dissecting hematomas</td>\n<td>Rare</td>\n<td>Characteristic (most common-iliopsoas)</td>\n</tr>\n<tr>\n<td>Laboratory tests</td>\n<td>Bleeding time is prolonged</td>\n<td>PT and/or PTT are prolonged</td>\n</tr>\n<tr>\n<td>Most common</td>\n<td>Inherited: VWD</td>\n<td>\n<p>Inherited: Hemophilia A</p>\n<p>Acquired: Hemorrhagic diathesis of liver disease</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>VWD:&nbsp;von Willebrand disease</p>\n<p>PT: Prothrombin time</p>\n<p>PTT: Partial thromboplastin time</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8446",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a disorder of platelet adhesion?",
      "choices": [
        {
          "id": 1,
          "text": "Glanzmann’s thrombasthenia"
        },
        {
          "id": 2,
          "text": "Bernard Soulier syndrome"
        },
        {
          "id": 3,
          "text": "Wiskott Aldrich syndrome"
        },
        {
          "id": 4,
          "text": "Hermansky Pudlak syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Bernard Soulier </strong>syndrome is a disorder of <strong>platelet adhesion</strong>.&nbsp;It occurs due to an inherited defect in the <strong>GPIb-IX</strong> complex.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/56f11346987e42ae8a45ab9a221cab9dx1280x2203.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8447",
      "difficulty": "easy"
    },
    {
      "text": "Patients with which of the following conditions would have a low platelet count?",
      "choices": [
        {
          "id": 1,
          "text": "Platelet storage pool disorder"
        },
        {
          "id": 2,
          "text": "Wiskott-Aldrich syndrome"
        },
        {
          "id": 3,
          "text": "Henoch-Schonlein purpura"
        },
        {
          "id": 4,
          "text": "Hemophilia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Thrombocytopenia</strong> is a feature of&nbsp;<strong>Wiskott-Aldrich</strong> syndrome.</p>\n<p>It is an <strong>X-linked</strong> recessive condition caused by mutations in the&nbsp;<strong>WASP </strong>gene. It affects <strong>T-cells </strong>and<strong> platelets</strong> and presents with the following features:&nbsp;</p>\n<ul>\n<li><strong>Eczema</strong></li>\n<li><strong>Thrombocytopenia</strong>&nbsp;- along with&nbsp;decreased platelet size, impaired platelet aggregation response</li>\n<li><strong>Immunodeficiency</strong>&nbsp;- low IgM, high IgE, defective regulatory T cells causing recurrent bacterial infections.</li>\n</ul>\n<p>Option A: Platelet storage pool disorder is a disorder of defective platelet granule formation.</p>\n<p>Option C: Henoch-Schonlein purpura is a type of small vessel&nbsp;vasculitis in children and young adults.</p>\n<p>Option D: Hemophilia is a coagulation disorder, hence the platelet count is not affected.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4059",
      "difficulty": "medium"
    },
    {
      "text": "Immune-mediated destruction of platelets is seen in patients with which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Bernard-Soulier syndrome"
        },
        {
          "id": 2,
          "text": "Hermansky-Pudlak syndrome"
        },
        {
          "id": 3,
          "text": "Thrombotic thrombocytopenic purpura"
        },
        {
          "id": 4,
          "text": "Drug-induced thrombocytopenia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Immune-mediated destruction</strong> of platelets is seen in <strong>drug-induced</strong>&nbsp;<strong>thrombocytopenia.</strong>&nbsp;Common drugs that cause this are quinidine, heparin, sulfa compounds.&nbsp;</p>\n<p>Drug-dependent antibody binding can only be demonstrated in the presence of the drug in the laboratory assays. The thrombocytopenia normally occurs within 21 days of initial exposure and usually gets resolved after 7-10 days once the drug is stopped.&nbsp;</p>\n<p>Immune-mediated destruction of platelets is seen in:</p>\n<ul>\n<li><strong>Drug-induced</strong> thrombocytopenia</li>\n<li><strong>Infection-induced</strong> thrombocytopenia</li>\n<li>Idiopathic/ immune thrombocytopenic purpura&nbsp;(ITP)</li>\n</ul>\n<p>Option A:&nbsp;Bernard-Soulier syndrome is a disorder of platelet adhesion. There are no autoantibodies against platelets.</p>\n<p>Option B: Hermansky-Pudlak syndrome is an&nbsp;inherited disorder with defective&nbsp;granule formation in platelets. It affects platelet activation and aggregation.</p>\n<p>Option C: Thrombotic microangiopathies like thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome&nbsp;(HUS) lead to thrombocytopenia due to increased platelet consumption.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4061",
      "difficulty": "medium"
    },
    {
      "text": "A young man comes to you with complaints of bleeding gums and the following skin rash. He reports that he had diarrhea last week after eating at a roadside eatery. History is significant for deep vein thrombosis 6 months ago that was treated with heparin. His CBC report revealed a platelet count of 15,000/µL, normal RBC and WBC count. His peripheral smear was normal. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Hemolytic uremic syndrome"
        },
        {
          "id": 2,
          "text": "Thrombotic thrombocytopenic purpura"
        },
        {
          "id": 3,
          "text": "Immune thrombocytopenic purpura"
        },
        {
          "id": 4,
          "text": "Heparin-induced thrombocytopenia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario and image showing <strong>petechiae</strong> are suggestive of <strong>immune thrombocytopenic purpura</strong>.</p>\n<p><strong>Immune thrombocytopenic purpura </strong>(ITP) is an acquired disorder with <strong>autoantibodies</strong> against platelet membrane glycoproteins<strong> IIb-IIIa</strong> or <strong>Ib-IX</strong>. It can either be primary (idiopathic) or secondary to autoimmune conditions like SLE or infections like HIV and hepatitis C.</p>\n<p>It presents with features of <strong>mucocutaneous</strong> <strong>bleeding</strong>. CBC shows isolated thrombocytopenia and peripheral smear does not reveal any hemolysis. </p>\n<table>\n<tbody>\n<tr>\n<td><strong>Acute ITP</strong></td>\n<td><strong>Chronic ITP</strong></td>\n</tr>\n<tr>\n<td>Common in children</td>\n<td>Common in adults (females &gt; males)</td>\n</tr>\n<tr>\n<td>Associated with an antecedent viral infection</td>\n<td>Not associated with antecedent infection</td>\n</tr>\n<tr>\n<td>Spontaneous remission in 80% cases</td>\n<td>Spontaneous remission is not usually seen</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Options <strong>A</strong> and <strong>B</strong>: HUS and TTP are microangiopathies. They are associated with <strong>hemolysis and schistocytes</strong> on peripheral smear. </p>\n<p>Option <strong>D:</strong> Heparin-induced thrombocytopenia typically presents <strong>within 5-10 days of treatment</strong>. Hence, it is not the likely diagnosis in this patient.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1839d0a0b6d64631b0d4aca0475d0791x1280x2203.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b9f86e5242b74faaaab53f43357ffe24.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8448",
      "difficulty": "medium"
    },
    {
      "text": "Two weeks after an upper respiratory tract infection, a 5-year-old presents with ecchymosis and petechiae all over the body. Abdominal examination revealed no hepatosplenomegaly. The platelet count is 15,000/µL and the coagulation profile is normal. Which of the following is false regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Peripheral blood smear is normal"
        },
        {
          "id": 2,
          "text": "Bone marrow biopsy shows increased megakaryocytes"
        },
        {
          "id": 3,
          "text": "Bleeding into the joints is a common manifestation"
        },
        {
          "id": 4,
          "text": "The condition resolves spontaneously in 80% patients"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This scenario is suggestive of <strong>acute immune thrombocytopenic purpura</strong>. Bleeding into the joints is seen in coagulation disorders and is not a manifestation&nbsp;of this condition.</p>\n<p>Immune thrombocytopenic purpura or&nbsp;idiopathic thrombocytopenic purpura&nbsp;<strong>(ITP)</strong> &nbsp;is an acquired disorder in which there is an immune-mediated destruction of platelets. It can be acute or chronic.</p>\n<p><strong>Acute ITP&nbsp;</strong>is common in children and is usually <strong>preceded</strong> by <strong>viral</strong> infection. It presents with mucocutaneous bleeding (epistaxis, petechiae, ecchymosis).&nbsp;Hepatomegaly, splenomegaly, lymphadenopathy, fever and jaundice are absent. The following laboratory features are seen:</p>\n<ul>\n<li>Thrombocytopenia (commonly&nbsp;&lt;20,000 / &mu;L)</li>\n<li>Bleeding time - prolonged</li>\n<li>PT/aPTT/INR - normal</li>\n<li>Bone marrow - normal/increased megakaryocytes</li>\n<li>Peripheral smear - normal</li>\n</ul>\n<p>This condition <strong>resolves</strong> <strong>spontaneously</strong> in 80% of the cases. Treatment is as follows:</p>\n<ul>\n<li>Platelet count &lt; 30,000 with risk factors for bleeding (antiplatelet drugs/anticoagulants or concomitant bleeding disorders): <strong>Oral glucocorticoids</strong> or <strong>IVIG</strong>&nbsp;</li>\n<li>Severe bleeding symptoms:&nbsp;<strong>IV methylprednisolone</strong>&nbsp;&plusmn;&nbsp;IVIG&nbsp;</li>\n<li>Life-threatening&nbsp;bleeding (like intracranial hemorrhage):&nbsp;<strong>platelet transfusion</strong> +&nbsp;IV methylprednisolone +&nbsp;IVIG&nbsp;</li>\n</ul><hr><h3>Related Pearl: Differences between Bleeding Disorders and Coagulation disorders</h3><table>\n<tbody>\n<tr>\n<td><strong>Finding</strong></td>\n<td><strong>Bleeding disorders</strong></td>\n<td><strong>Coagulation disorders</strong></td>\n</tr>\n<tr>\n<td>Cause</td>\n<td>\n<p>Quantitative/ Qualitative platelet abnormality</p>\n</td>\n<td>Deficiency of clotting factors</td>\n</tr>\n<tr>\n<td>Sex</td>\n<td>More common in females (commonly autoimmune)</td>\n<td>More common in males (commonly X-linked)</td>\n</tr>\n<tr>\n<td>Family history</td>\n<td>Rare (except in VWD)</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Petechiae</td>\n<td>Characteristic</td>\n<td>&nbsp;Rare</td>\n</tr>\n<tr>\n<td>Superficial ecchymosis</td>\n<td>Small and Multiple</td>\n<td>Large and Solitary</td>\n</tr>\n<tr>\n<td>Bleeding from superficial cuts&nbsp;</td>\n<td>Profuse</td>\n<td>Minimal persistent</td>\n</tr>\n<tr>\n<td>Hemarthrosis</td>\n<td>Rare</td>\n<td>Characteristic (most common-knee)</td>\n</tr>\n<tr>\n<td>Deep dissecting hematomas</td>\n<td>Rare</td>\n<td>Characteristic (most common-iliopsoas)</td>\n</tr>\n<tr>\n<td>Laboratory tests</td>\n<td>Bleeding time is prolonged</td>\n<td>PT and/or PTT are prolonged</td>\n</tr>\n<tr>\n<td>Most common</td>\n<td>Inherited: VWD</td>\n<td>\n<p>Inherited: Hemophilia A</p>\n<p>Acquired: Hemorrhagic diathesis of liver disease</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>VWD:&nbsp;von Willebrand disease</p>\n<p>PT: Prothrombin time</p>\n<p>PTT: Partial thromboplastin time</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4063",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old woman comes to the ER after developing a spontaneous nosebleed. Over the past 1 week, she has noticed blood on her toothbrush while brushing her teeth. She was diagnosed with hepatitis C three months ago. Investigations reveal a platelet count of 32,000/ µL and a bleeding time of 9 minutes . Which of the following is false regarding the treatment of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "She requires regular platelet transfusions until platelet count is normalized"
        },
        {
          "id": 2,
          "text": "Prednisone  or anti-D immunoglobulins can be used as the first-line treatment"
        },
        {
          "id": 3,
          "text": "Splenectomy may be done if she relapses after medical management"
        },
        {
          "id": 4,
          "text": "Romiplostim and eltrombopag can be used if there is no response to splenectomy"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>This clinical scenario in an <strong>adult</strong> patient is suggestive of <strong>chronic ITP</strong> (idiopathic thrombocytopenic purpura). She does not require <strong>platelet transfusion</strong>.&nbsp;It is recommended only for patients with <strong>severe bleeding </strong>manifestations&nbsp;(intracranial/ gastrointestinal) or platelet count<strong> &lt; 5000&nbsp;&mu;L.</strong></p>\n<p>Chronic ITP can either be <strong>primary</strong> (idiopathic) or <strong>secondary</strong> to autoimmune conditions like SLE or infections like HIV and <strong>hepatitis C</strong>. Depending on the clinical features, the management is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Clinical features</strong></td>\n<td><strong>Management</strong></td>\n</tr>\n<tr>\n<td>\n<p>1. &nbsp;&nbsp;</p>\n</td>\n<td>\n<p>Minor bleeding manifestations (and/or)</p>\n<p>Platelet count &gt; 5000/&nbsp;&mu;L</p>\n</td>\n<td>\n<p><strong>Prednisone</strong> (OR)</p>\n<p><strong>Anti-D</strong> <strong>immunoglobulin</strong> therapy - effective only in Rh-positive patients (OR)</p>\n<p>Intravenous immunoglobulin (<strong>IVIG</strong>)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2. &nbsp;</p>\n</td>\n<td>\n<p>Severe ITP (any of the following):</p>\n<ul>\n<li>Significant GI / intracranial bleeding</li>\n<li>Platelet count &lt; 5000/&mu;L</li>\n<li>Signs of impending bleeding (retinal or large oral mucosal bleeds)</li>\n</ul>\n</td>\n<td>\n<p>Platelet transfusion (AND)</p>\n<p>High-dose glucocorticoids (AND)</p>\n<p>IVIG / Anti-D immunoglobulins + Rituximab</p>\n</td>\n</tr>\n<tr>\n<td>3. &nbsp;</td>\n<td>Relapse after first-line therapy</td>\n<td><strong>Splenectomy</strong></td>\n</tr>\n<tr>\n<td>4. &nbsp;&nbsp;</td>\n<td>Unresponsive to all other therapy or relapse after splenectomy</td>\n<td>Thrombopoietin receptor agonists - <strong>romiplostim</strong> (subcutaneous), <strong>eltrombopag</strong> (oral)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4069",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the best treatment for the relapse of immune thrombocytopenic purpura?",
      "choices": [
        {
          "id": 1,
          "text": "IV immunoglobulins"
        },
        {
          "id": 2,
          "text": "Steroids"
        },
        {
          "id": 3,
          "text": "Splenectomy"
        },
        {
          "id": 4,
          "text": "Blood transfusion"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Splenectomy</strong> is the treatment of choice in a case of <strong>immune thrombocytopenic purpura</strong> (ITP) relapse after <strong>first line therapy</strong> with <strong>glucocorticoids</strong>. The relapse usually occurs once they are tapered. <strong>Vaccination</strong> against encapsulated organisms (pneumococcus, meningococcus, H. influenzae) is advised before splenectomy is performed.</p>\n<p>It is important to note that in some patients <strong>ITP resolves by itself,</strong> and observation along with intermittent <strong>IV immunoglobulins</strong> and <strong>anti - Rh(D)</strong> administration or administration of a <strong>thrombopoietin receptor agonist</strong> (eltrombopag, romiplostim) can be a viable option before splenectomy is considered.</p>\n<p>The treatment of ITP is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>Clinical features</td>\n<td>Management</td>\n</tr>\n<tr>\n<td>\n<p>1. &nbsp;&nbsp;</p>\n</td>\n<td>\n<p>Minor bleeding manifestations (and/or)</p>\n<p>Platelet count &gt; 5000/&nbsp;&mu;L</p>\n</td>\n<td>\n<p><strong>Prednisone</strong> (OR)</p>\n<p><strong>Anti-D immunoglobulin therapy</strong> - effective only in Rh-positive patients (OR)</p>\n<p>Intravenous immunoglobulin (IVIG)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2. &nbsp;</p>\n</td>\n<td>\n<p>Severe ITP (any of the following):</p>\n<ul>\n<li>Significant GI / intracranial bleeding</li>\n<li>Platelet count &lt; 5000/&mu;L</li>\n<li>Signs of impending bleeding (retinal or large oral mucosal bleeds)</li>\n</ul>\n</td>\n<td>\n<p>Platelet transfusion (AND)</p>\n<p>High-dose glucocorticoids (AND)</p>\n<p>IVIG / Anti-D immunoglobulins + Rituximab</p>\n</td>\n</tr>\n<tr>\n<td>3. &nbsp;</td>\n<td>Relapse after first-line therapy</td>\n<td><strong>Splenectomy</strong></td>\n</tr>\n<tr>\n<td>4. &nbsp;&nbsp;</td>\n<td>Unresponsive to all other therapy or relapse after splenectomy</td>\n<td>Thrombopoietin receptor agonists - <strong>romiplostim</strong> (subcutaneous), <strong>eltrombopag</strong> (oral)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ITP is an <strong>acquired</strong> disorder characterized by the <strong>immune-mediated</strong> destruction of platelets and possibly inhibition of platelet release from the megakaryocyte. Secondary causes of ITP include systemic lupus erythematosus (<strong>SLE</strong>), <strong>HIV-AIDS</strong>, and <strong>Hepatitis C</strong>.</p>\n<p>ITP usually presents with <strong>mucocutaneous bleeding</strong>, <strong>very low platelet count</strong>, and normal peripheral blood cells. Patients typically exhibit ecchymoses and petechiae or they may incidentally discover thrombocytopenia during a routine complete blood count.&nbsp;Rarely, life-threatening bleeding may occur. The presence of <strong>wet purpura</strong> (blood blisters in the mouth) and <strong>retinal hemorrhages</strong> can serve as <strong>warning signs</strong> of potentially life-threatening bleeding.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7483",
      "difficulty": "medium"
    },
    {
      "text": "It is your first day as an intern in the medicine ward. The senior resident tells you to check the platelet count of a patient who is being monitored for thrombocytopenia. He was started on a new medication the previous night. What drug was most likely prescribed?",
      "choices": [
        {
          "id": 1,
          "text": "Phenytoin"
        },
        {
          "id": 2,
          "text": "Ampicillin"
        },
        {
          "id": 3,
          "text": "Abciximab"
        },
        {
          "id": 4,
          "text": "Amiodarone"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Abciximab</strong> can cause a drop in platelet count&nbsp;within<strong> 24 hours</strong> of initial exposure. Hence, these patients must be monitored for <strong>thrombocytopenia.</strong>&nbsp;This is due to naturally-occurring <strong>antibodies</strong> that cross-react with the drug bound to the platelets.</p>\n<p>Thrombocytopenia due to <strong>other drugs</strong> typically occurs <strong>several days</strong> after exposure (average 21 days) and resolves in 7-10 days after drug withdrawal. &nbsp;Drug-induced thrombocytopenia can occur due to the following mechanisms:</p>\n<ul>\n<li>Bone&nbsp;marrow suppression - chemotherapeutic drugs</li>\n<li>Drug dependent antibodies that react with platelet surface antigens - quinine and sulfonamides</li>\n<li>Naturally occurring antibodies that cross-react with drugs bound to the platelets - platelet Gp IIb/IIIa inhibitors</li>\n</ul>\n<p>Some of the drugs that cause thrombocytopenia are:</p>\n<ul>\n<li>Antibiotics - <strong>ampicillin</strong>, cephalosporins, piperacillin, vancomycine</li>\n<li>Analgesics - ibuprofen, acetaminophen</li>\n<li>Anti-epileptics - <strong>phenytoin</strong>, carbamazepine</li>\n<li>Heparin</li>\n<li><strong>Amiodarone</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4073",
      "difficulty": "medium"
    },
    {
      "text": "Patients with all of the following usually present with bleeding except:",
      "choices": [
        {
          "id": 1,
          "text": "Heparin-induced thrombocytopenia"
        },
        {
          "id": 2,
          "text": "Drug-induced thrombocytopenia"
        },
        {
          "id": 3,
          "text": "Inherited thrombocytopenia"
        },
        {
          "id": 4,
          "text": "Infection-induced thrombocytopenia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Heparin-induced thrombocytopeni</strong>a (HIT) is not associated with bleeding. On the contrary, it is associated with an increased risk of <strong>thrombosis</strong>.</p>\n<p>This condition&nbsp;occurs due to&nbsp;the production of <strong>antibodies </strong>against<strong>&nbsp;</strong>the<strong> heparin-PF4 complex</strong> (platelet factor 4, a platelet-specific protein). These antibodies can <strong>activate platelets</strong> and result in thrombosis. It is seen 5-14 days after exposure to heparin.</p>\n<p>These antibodies can be detected using ELISA or serotonin release assay. This condition is managed by <strong>discontinuing heparin</strong> and using alternative anticoagulants.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1542",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following cannot be used in the treatment of patients with heparin-induced thrombocytopenia?",
      "choices": [
        {
          "id": 1,
          "text": "Danaparoid"
        },
        {
          "id": 2,
          "text": "Lepirudin"
        },
        {
          "id": 3,
          "text": "Argatroban"
        },
        {
          "id": 4,
          "text": "Enoxaparin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Low molecular weight heparin (LMWH) such as <strong>enoxaparin</strong> cannot be used in the treatment of&nbsp;heparin-induced thrombocytopenia (HIT). This is because <strong>HIT antibodies</strong> (against anti-PF4-heparin complex) may&nbsp;<strong>cross-react</strong> with LMWH.</p>\n<p>HIT can occur following exposure to unfractionated heparin and less commonly with LMWH.</p>\n<p>The treatment of HIT is as follows:</p>\n<ul>\n<li><strong>Discontinue</strong><strong>&nbsp;heparin</strong></li>\n<li>Anticoagulation with <strong>non-heparin anticoagulants</strong> even in the absence of thrombosis, since there&nbsp;is a high risk of thrombosis.\n<ul>\n<li>Direct thrombin inhibitors: Argatroban, lepirudin, bivalirudin</li>\n<li>Danaparoid (heparinoid)</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1543",
      "difficulty": "medium"
    },
    {
      "text": "The CBC of a 33-year-old woman revealed a low platelet count. However, further evaluation revealed this to be an in vitro sampling error. Which of the following is the likely cause of this finding?",
      "choices": [
        {
          "id": 1,
          "text": "EDTA"
        },
        {
          "id": 2,
          "text": "Sodium citrate"
        },
        {
          "id": 3,
          "text": "Heparin"
        },
        {
          "id": 4,
          "text": "Finger stick sample"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>This scenario is suggestive of <strong>pseudothrombocytopenia</strong>. It is seen in blood samples collected with <strong>EDTA</strong> as the anticoagulant.</p>\n<p>EDTA causes a <strong>reduction</strong> in the <strong>calcium</strong> content of the collected blood sample. This triggers in vitro <strong>platelet</strong> <strong>clumping</strong> and agglutination by antibodies (usually IgG), as shown below:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4f203d48f03b432f94a70bab3cd4348fx750x600.JPEG\" alt=\"Explanation Image\"><p>When a low platelet count is obtained with an EDTA sample, the peripheral blood smear should be evaluated. The platelet count must also be determined in blood collected in&nbsp;<strong>sodium citrate </strong>or<strong> heparin&nbsp;</strong>collection tubes&nbsp;or fresh<strong> fingerstick</strong>&nbsp;blood <strong>sample.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1545",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is false regarding patients with Bernard-Soulier syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "Platelet aggregation tests with epinephrine and ADP are normal"
        },
        {
          "id": 2,
          "text": "Ristocetin aggregation test is normal"
        },
        {
          "id": 3,
          "text": "Peripheral smear shows large platelets"
        },
        {
          "id": 4,
          "text": "Mild thrombocytopenia is seen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> ristocetin aggregation</strong> test is <strong>abnormal</strong>&nbsp;(no aggregation) in patients with <strong>Bernard-Soulier</strong>&nbsp;(BS) syndrome.</p>\n<p>It is an inherited disorder of platelet function or <strong>qualitative</strong>&nbsp;platelet disorder due to deficiency of the&nbsp;<strong>Gp&nbsp;Ib-IX </strong>receptor. This is the platelet membrane receptor&nbsp;for the von Willebrand factor (vWF). The binding of&nbsp;the <strong>vWF</strong> to the GpIb-IX-V complex on the platelet membrane is essential for <strong>platelet adhesion</strong> to the vessel wall.</p>\n<p>This condition presents with <strong>mild&nbsp;thrombocytopenia</strong> and peripheral&nbsp;smear shows <strong>large platelets</strong>.</p>\n<p>Platelet aggregation tests are performed to measure platelet activation and aggregation in vitro. Various platelet agonists like ADP, epinephrine, collagen, and ristocetin can be used to perform these tests. In&nbsp;Bernard-Soulier syndrome, the following responses are seen:</p>\n<ul>\n<li>With ristocetin - No response/no aggregation, as <strong>ristocetin&nbsp;</strong>specifically <strong>binds</strong> to the platelet membrane via the&nbsp;<strong>Gp Ib-IXa </strong>receptor</li>\n<li>With <strong>ADP</strong> or <strong>epinephrine</strong> - <strong>Normal response</strong>, as Gp IIb-IIIa receptor is not involved in this process</li>\n</ul><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4077",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most common inherited bleeding disorder?",
      "choices": [
        {
          "id": 1,
          "text": "Hemophilia A"
        },
        {
          "id": 2,
          "text": "Hemophilia B"
        },
        {
          "id": 3,
          "text": "Immune thrombocytopenia purpura"
        },
        {
          "id": 4,
          "text": "Von Willebrand disease"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Von Willebrand disease</strong> (vWD) is the most common inherited bleeding disorder.</p>\n<p>vWD occurs due to deficient or abnormal von Willebrand&nbsp;factor (vWF).&nbsp;vWF is synthesized by endothelial cells and megakaryocytes (gene located on chromosome 12p). It is then stored in endothelial storage vesicles, <strong>Weibel-Palade bodies.&nbsp;</strong>Metalloprotease <strong>ADAMTS13</strong>&nbsp;cleaves ultra-large multimers of VWF which are responsible for platelet adhesion.</p>\n<p>The functions of vWF and the corresponding symptoms include:</p>\n<ul>\n<li><strong>Adhesion</strong> of&nbsp;the <strong>platelets</strong>&nbsp;to the exposed subendothelium - symptoms of both platelet and bleeding disorders</li>\n<li>Prolongs the half-life&nbsp;of<strong>&nbsp;factor VIII</strong>&nbsp;by binding to it in circulation - hemophilia A like symptoms (rare)</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1475",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is called autosomal hemophilia?",
      "choices": [
        {
          "id": 1,
          "text": "Type 2M von Willebrand disease"
        },
        {
          "id": 2,
          "text": "Type 2N von Willebrand disease"
        },
        {
          "id": 3,
          "text": "Type 2A von Willebrand disease"
        },
        {
          "id": 4,
          "text": "Type 2B von Willebrand disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Autosomal hemophilia</strong>&nbsp;is also called <strong>type 2N </strong>von Willebrand disease (<strong>vWD</strong>), as the clinical presentation is similar to hemophilia.</p>\n<p>The types of vWD are:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Inheritance</strong></td>\n<td><strong>Mechanism</strong></td>\n<td><strong>Important characteristics</strong></td>\n</tr>\n<tr>\n<td>1</td>\n<td>AD</td>\n<td>Partial quantitative deficiency of VWF</td>\n<td><strong>Most common</strong> type</td>\n</tr>\n<tr>\n<td>3</td>\n<td>AR</td>\n<td>Complete quantitative deficiency</td>\n<td>Most severe&nbsp;VWD</td>\n</tr>\n<tr>\n<td>2A</td>\n<td>AD</td>\n<td>Loss of VWF multimers (increased cleavage by ADAMS13)</td>\n<td>Platelet adhesion defect</td>\n</tr>\n<tr>\n<td>2B</td>\n<td>AD</td>\n<td>Increased binding of VWF to platelets causing VWF-platelet complex destruction</td>\n<td>Thrombocytopenia</td>\n</tr>\n<tr>\n<td>2M</td>\n<td>AD</td>\n<td>Decreased affinity of VWF to platelets</td>\n<td>Platelet adhesion defect, very rare</td>\n</tr>\n<tr>\n<td>2N</td>\n<td><strong>AR</strong></td>\n<td>Decreased affinity of VWF to Factor VIII</td>\n<td><strong>Autosomal hemophilia</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>In pseudo vWD,&nbsp;the vWF is normal. However, platelets have an increased affinity for vWF. It presents similar to vWD 2B with thrombocytopenia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1523",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following patients has Heyde's syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "A man with aortic stenosis with gastrointestinal bleeding"
        },
        {
          "id": 2,
          "text": "A woman with aortic stenosis with intracranial bleed"
        },
        {
          "id": 3,
          "text": "A man with aortic regurgitation with gastrointestinal bleeding"
        },
        {
          "id": 4,
          "text": "A woman with aortic regurgitation with intracranial bleed"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Heyde&rsquo;s</strong> syndrome is<strong>&nbsp;aortic stenosis</strong> with <strong>gastrointestinal bleeding,&nbsp;</strong>due to&nbsp;<strong>angiodysplasia </strong>of the gastrointestinal tract.</p>\n<p>The shear stress on blood passing through the stenotic aortic valve&nbsp;produces a change in the von Willebrand factor making it susceptible to serum proteases. Hence, large multimer forms are lost, leading to an <strong>acquired type 2 </strong>von Willebrand disease (<strong>vWD</strong>).&nbsp;The condition is reversed with the replacement of the aortic valve.</p>\n<p>Other causes of <strong>acquired</strong> <strong>vWD</strong> include:</p>\n<ul>\n<li>Multiple myeloma</li>\n<li>Non-Hodgkin's lymphoma</li>\n<li>Polycythemia vera</li>\n<li>Systemic lupus erythematosus</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1479",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following laboratory findings is seen in a patient with von Willebrand's disease?",
      "choices": [
        {
          "id": 1,
          "text": "Normal ristocetin aggregation test"
        },
        {
          "id": 2,
          "text": "Increased bleeding time"
        },
        {
          "id": 3,
          "text": "Increased prothrombin time"
        },
        {
          "id": 4,
          "text": "Decreased activated partial thromboplastin time"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Bleeding time</strong> is <strong>increased</strong> in von Willebrand&nbsp;disease (<strong>vWD</strong>). It is a combination of a&nbsp;platelet adhesion defect with factor VIII deficiency.</p>\n<p>The laboratory findings in vWD include:&nbsp;</p>\n<ul>\n<li>Platelet count is normal (except type 2B)</li>\n<li>Bleeding time&nbsp;is prolonged&nbsp;</li>\n<li><strong>Ristocetin aggregation </strong>is<strong> abnormal</strong></li>\n<li>Other platelet aggregation tests are normal</li>\n<li>Prothrombin time (PT) is normal</li>\n<li><strong>aPTT </strong>is<strong> prolonged</strong></li>\n<li>VWF activity is decreased</li>\n<li>Factor VIII activity is decreased</li>\n</ul><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1524",
      "difficulty": "easy"
    },
    {
      "text": "A 28-year-old woman is being evaluated for prolonged bleeding following a tooth extraction. She also reports heavy bleeding during menses and recurrent gum bleeds. Labs show increased aPTT, normal PT, and increased bleeding time. Which of the following is the first-line treatment for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Tranaxemic acid"
        },
        {
          "id": 2,
          "text": "Factor VIII concentrate"
        },
        {
          "id": 3,
          "text": "Von Willebrand factor concentrate"
        },
        {
          "id": 4,
          "text": "Desmopressin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This clinical scenario is suggestive of <strong>von Willebrand's disease</strong>. The preferred first-line treatment is <strong>desmopressin </strong>(DDAVP).</p>\n<p>This drug acts on endothelial<strong> V2 receptors</strong> causing the <strong>release</strong> of <strong>VWF</strong> and <strong>factor VIII</strong> from endothelial stores. DDAVP can be given intravenously or by an intranasal spray. The side effects include tachyphylaxis and hyponatremia. </p>\n<p><strong>VWF</strong> <strong>concentrate</strong> and <strong>factor VIII</strong> <strong>concentrate</strong> are reserved for patients with <strong>severe disease</strong> or prior to major procedures. Antifibrinolytic therapy (tranexamic acid or ε-aminocaproic acid) may be used for the prevention and treatment of mucosal bleeding.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1528",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following features is not seen in patients with Glanzmann’s thrombasthenia?",
      "choices": [
        {
          "id": 1,
          "text": "Abnormal platelet aggregation on adding ADP"
        },
        {
          "id": 2,
          "text": "Decreased platelet count"
        },
        {
          "id": 3,
          "text": "Normal von Willebrand  factor levels"
        },
        {
          "id": 4,
          "text": "Normal platelet aggregation to ristocetin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Thrombocytopenia is not seen in <strong>Glanzmann&rsquo;s</strong> <strong>thrombasthenia</strong>.</p>\n<p>Glanzmann&rsquo;s thrombasthenia is a <strong>primary defect</strong> of platelet function (<strong>aggregation</strong>). It occurs due to congenital <strong>absence</strong> of the <strong>GpIIb/IIIa&nbsp;</strong>receptor. It presents as superficial mucocutaneous bleeding with normal platelet count and single <strong>isolated platelets</strong> without clumping on peripheral smear.&nbsp;The levels of <strong>vWF</strong> are <strong>normal</strong>.</p>\n<p>Normally, release of ADP causes platelets to change shape and bind to fibrinogen through the GpIIb/IIIa receptor. In Glanzmann&rsquo;s thrombasthenia, absence of the receptor causes <strong>abnormal</strong> <strong>aggregation</strong>&nbsp;(absent or reduced) on adding <strong>ADP</strong>. However, aggregation in response to <strong>ristocetin</strong> is <strong>normal</strong>, as it is dependent on GpIb and vWF.</p>\n<p>Secondary platelet dysfunction can be seen in the following conditions:</p>\n<ul>\n<li>Uremia</li>\n<li>Paraproteinemia</li>\n<li>Myeloproliferative disorders</li>\n</ul><hr><h3>Related Pearl: Platelet disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8a852ed6ad094d22b4add695e1529e87x1280x1740.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Finding</strong></p>\n</td>\n<td>\n<p><strong>Bernard&ndash;Soulier syndrome</strong></p>\n</td>\n<td>\n<p><strong>Glanzmann&rsquo;s thrombasthenia</strong></p>\n</td>\n<td>\n<p><strong>von Willebrand Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Inheritance</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>\n<p>Autosomal recessive</p>\n</td>\n<td>Most common (type 1): Autosomal dominant</td>\n</tr>\n<tr>\n<td>&nbsp;Defect</td>\n<td>\n<p>Absence of Gp Ib-IX-V receptor</p>\n</td>\n<td>Absence of&nbsp;Gp IIb/IIIa receptor</td>\n<td>\n<p>Type 1: Partial quantitative deficiency of&nbsp;von Willebrand factor (VWF)</p>\n<p>Type 2: Qualitative defect of VWF</p>\n<p>Type 3: Complete quantitative deficiency of VWF&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Mechanism</td>\n<td>\n<p>Lack of Gp Ib-IX-V prevents platelet <strong>adhesion</strong> to VWF</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Platelets cannot <strong>aggregate</strong> as Gp IIb/IIIa normally binds&nbsp;fibrinogen and forms bridges between platelets&nbsp;</p>\n</td>\n<td>\n<p>There are 2 mechanisms:</p>\n<p>Platelet <strong>adhesion</strong> defect - due to absent vWF that normally binds to GPIB-IX and collagen in the subendothelium</p>\n<p>Factor VIII deficiency as&nbsp;vWF usually prevents its degradation</p>\n</td>\n</tr>\n<tr>\n<td>Platelet count&nbsp;</td>\n<td>Normal platelet count/ mild thrombocytopenia&nbsp;</td>\n<td>Normal</td>\n<td>Normal (except in type 2B- thrombocytopenia)</td>\n</tr>\n<tr>\n<td>Platelet morphology</td>\n<td>Large platelets/ megathrombocytes with dense granules</td>\n<td>Normal</td>\n<td>&nbsp;Normal/ large</td>\n</tr>\n<tr>\n<td>Bleeding time</td>\n<td>\n<p>Prolonged</p>\n</td>\n<td>Prolonged</td>\n<td>&nbsp;Prolonged</td>\n</tr>\n<tr>\n<td>Platelet aggregation tests (collagen, ADP, thrombin)</td>\n<td>Normal</td>\n<td>Abnormal</td>\n<td>&nbsp;Normal</td>\n</tr>\n<tr>\n<td>Ristocetin aggregation test</td>\n<td>\n<p>Abnormal (platelets does not aggregate)</p>\n<p>Does not normalize&nbsp;after addition of normal serum</p>\n</td>\n<td>\n<p>Normal</p>\n<p>(aggregation of platelets)</p>\n</td>\n<td>Abnormal, Normalizes after addition of normal serum</td>\n</tr>\n<tr>\n<td>VWF factor levels</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;Decreased</td>\n</tr>\n<tr>\n<td>PT/PTT</td>\n<td>Normal</td>\n<td>Normal</td>\n<td>&nbsp;PT normal, aPTT prolonged</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4079",
      "difficulty": "medium"
    },
    {
      "text": "A physician decides to start a patient with stroke on antiplatelet medication. All of the following drugs would be effective except:",
      "choices": [
        {
          "id": 1,
          "text": "Clopidogrel"
        },
        {
          "id": 2,
          "text": "Ticlopidine"
        },
        {
          "id": 3,
          "text": "Ticagrelor"
        },
        {
          "id": 4,
          "text": "Pagoclone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Pagoclone is an anxiolytic medication. It is not an antiplatelet drug.</p>\n<p>The thienopyridine drugs are ADP receptor or&nbsp;<strong>P2Y12 antagonists</strong>&nbsp;that inhibit ADP mediated platelet aggregation. They include the following drugs:</p>\n<ul>\n<li><strong>Clopidogrel</strong> - commonly used</li>\n<li><strong>Ticagrelor</strong> -&nbsp;reversible drug with a shorter t<sub>1/2</sub>, does not require activation, may cause mild, self-limited dyspnea&nbsp;</li>\n<li>Prasugrel -&nbsp;10 times more potent than clopidogrel, rapid onset of action, better absorption, more predictable&nbsp;</li>\n<li><strong>Ticlopidine</strong></li>\n</ul>\n<p>Clopidogrel and prasugrel are prodrugs that require <strong>activation</strong> by <strong>cytochrome P450</strong> enzymes.&nbsp;CYP2C19 polymorphisms can cause&nbsp;reduced platelet inhibition with clopidogrel and increased risk of cardiovascular events.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1517",
      "difficulty": "medium"
    },
    {
      "text": "A 24-year-old woman underwent evaluation for bleeding manifestations and severe anemia. Investigations revealed combined autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Evans syndrome"
        },
        {
          "id": 2,
          "text": "May-Hegglin anomaly"
        },
        {
          "id": 3,
          "text": "Fechtner syndrome"
        },
        {
          "id": 4,
          "text": "Rosenthal syndrome"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Combined autoimmune hemolytic anemia (<strong>AIHA</strong>) and idiopathic thrombocytopenic purpura (<strong>ITP</strong>) is called <strong>Evans syndrome</strong>.</p>\n<p>Options B and C: May-Hegglin anomaly and Fechtner syndrome are autosomal dominant hereditary conditions presenting with bleeding, sensorineural hearing loss, glomerulonephritis, and/or eye abnormalities.&nbsp;The severity of the bleeding symptoms is out of proportion to the moderately decreased platelet count.</p>\n<p>Option D: Rosenthal syndrome or hemophilia C&nbsp;refers to factor XI deficiency.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1460",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common side effect experienced by patients taking enteric-coated aspirin?",
      "choices": [
        {
          "id": 1,
          "text": "Gastrointestinal symptoms"
        },
        {
          "id": 2,
          "text": "Aspirin sensitivity"
        },
        {
          "id": 3,
          "text": "Aspirin tolerance"
        },
        {
          "id": 4,
          "text": "Medication overuse headache"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common side effect of <strong>aspirin</strong> is <strong>gastrointestinal</strong> symptoms. The use of enteric-coated aspirin does not reduce these side effects.</p>\n<p>Aspirin irreversibly acetylates and <strong>inhibits</strong> platelet cyclooxygenase <strong>(COX)-1,&nbsp;</strong>which causes reduced synthesis of <strong>thromboxane A2. </strong>At high doses, it also inhibits <strong>COX-2</strong>,&nbsp;which results in the <strong>anti-inflammatory</strong>&nbsp;effects of aspirin.</p>\n<p>The major GI side effects include&nbsp;dyspepsia, erosive gastritis, peptic ulcers with bleeding and perforation.&nbsp;The overall risk of <strong>major bleeding</strong> with aspirin is 1&ndash;3% per year, which increases 2-3 fold if there is concurrent use of&nbsp;other antiplatelet drugs or anticoagulants. The risk of bleeding can be <strong>reduced</strong> by <strong>eradication</strong> of <strong><em>Helicobacter pylori</em></strong> infection and giving proton pump inhibitors (<strong>PPIs</strong>).</p>\n<p><strong>Aspirin sensitivity&nbsp;</strong>refers to&nbsp;bronchospasm or urticaria/angioedema seen immediately after administration of aspirin. It is also called <strong>Samter's</strong> <strong>triad</strong> (asthma, recurrent nasal polyps, aspirin sensitivity).&nbsp;In patients with&nbsp;<strong>aspirin resistance,</strong>&nbsp;there is failure of aspirin to produce its normal platelet inhibitory functions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1512",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect about the mechanism of action of dipyridamole?",
      "choices": [
        {
          "id": 1,
          "text": "Increases levels of cyclic AMP in platelets"
        },
        {
          "id": 2,
          "text": "Blocks the reuptake of adenosine"
        },
        {
          "id": 3,
          "text": "Inhibits phosphodiesterase-mediated cyclic AMP degradation"
        },
        {
          "id": 4,
          "text": "Increases intracellular adenosine levels"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Dipyridamole</strong>&nbsp;increases <strong>extracellular adenosine</strong> levels.</p>\n<p>It is an antiplatelet drug that <strong>increases</strong> levels of cyclic AMP (<strong>cAMP</strong>) in platelets by:</p>\n<ul>\n<li>Blocking the reuptake of adenosine and increasing extracellular adenosine levels</li>\n<li>Inhibiting phosphodiesterase-mediated&nbsp;cAMP degradation</li>\n</ul>\n<p>This increase in cyclic AMP reduces intracellular levels of calcium. This inhibits platelet activation and aggregation.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/83f105195b784a118f2d762379820034x1280x1308.JPEG\" alt=\"Explanation Image\"><p>Dipyridamole is a weak antiplatelet used in combination with aspirin for the prevention of stroke in patients with TIA.</p>\n<p>Side effects include gastrointestinal and vasodilatory complaints (headache, flushing, dizziness, hypotension).&nbsp;Due to it's vasodilatory effects, it is contraindicated in patients with symptomatic coronary artery disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1514",
      "difficulty": "medium"
    },
    {
      "text": "A 62-year-old man diagnosed with myocardial infarction is planned for percutaneous intervention. He was diagnosed with diabetic nephropathy 2 months ago. The cardiologist decides to start him on aspirin and an additional antiplatelet drug. Which of the following can be used for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Abciximab only"
        },
        {
          "id": 2,
          "text": "Abciximab or eptifibatide"
        },
        {
          "id": 3,
          "text": "Tirofiban or eptifibatide"
        },
        {
          "id": 4,
          "text": "Tirofiban only"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Abciximab</strong> is <strong>safe</strong> in patients with <strong>renal impairment</strong>. It belongs to the&nbsp;group of&nbsp;<strong>GpIIb-IIIa</strong> receptor antagonists. These are&nbsp;parenteral drugs that are used in the management of patients with acute coronary syndrome.</p>\n<p>There are three important drugs in this group:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Feature</strong></td>\n<td><strong>Abciximab</strong></td>\n<td><strong>Eptifibatide</strong></td>\n<td><strong>Tirofiban</strong></td>\n</tr>\n<tr>\n<td>Gp IIb/IIIa antagonist</td>\n<td>&nbsp;Non-specific</td>\n<td>Specific</td>\n<td>Specific</td>\n</tr>\n<tr>\n<td>Plasma half-life</td>\n<td>Short (min)</td>\n<td>Long (2.5 h)</td>\n<td>Long (2.0 h)</td>\n</tr>\n<tr>\n<td>Platelet-bound half-life</td>\n<td>Long (days)</td>\n<td>Short (s)</td>\n<td>Short (s)</td>\n</tr>\n<tr>\n<td>Renal clearance</td>\n<td>No</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Immune-mediated <strong>thrombocytopenia</strong> and bleeding are the most common side effects. Thrombocytopenia can occur <strong>within 24 hours</strong> of initiation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1518",
      "difficulty": "hard"
    },
    {
      "text": "Plasmapheresis is the mainstay of treatment in patients with which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Autoimmune hemolytic anemia"
        },
        {
          "id": 2,
          "text": "Disseminated intravascular coagulation"
        },
        {
          "id": 3,
          "text": "Thrombotic thrombocytopenic purpura"
        },
        {
          "id": 4,
          "text": "Hemolytic uremic syndrome"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Plasmapheresis</strong> is the mainstay of the treatment of patients with thrombotic thrombocytopenic purpura (<strong>TTP</strong>).</p>\n<p>The best response to this therapy is seen in patients with <strong>ADAMTS13</strong> <strong>autoantibodies</strong>. Plasmapheresis is continued until the resolution of platelet count and signs of hemolysis for at least 2 days.</p>\n<p>Option A: The first line of treatment of autoimmune hemolytic anemia is glucocorticoids. The second line includes rituximab and splenectomy.</p>\n<p>Option B: Treatment of disseminated intravascular coagulation is primarily supportive with measures to treat the underlying cause.</p>\n<p>Option D: Treatment of HUS is primarily supportive<strong>.</strong> Dialysis is usually required. In some varients of HUS plasma infusion/exchange can be effective by replasing the complement-regulatory proteins.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4072",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not seen in patients with thrombotic thrombocytopenic purpura?",
      "choices": [
        {
          "id": 1,
          "text": "Hemolytic anemia"
        },
        {
          "id": 2,
          "text": "Focal neurological deficits"
        },
        {
          "id": 3,
          "text": "Venous thromboembolism"
        },
        {
          "id": 4,
          "text": "Elevated serum creatinine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Large vessel arterial or venous thromboemboli are not seen in&nbsp;thrombotic thrombocytopenic purpura (<strong>TTP</strong>). This condition is associated with&nbsp;<strong>microvascular</strong> thrombosis.</p>\n<p><strong>TTP</strong>&nbsp;occurs due to deficiency or autoantibodies against the metalloprotease <strong>ADAMTS13</strong>, which normally cleaves multimers of vWF. In this condition, the vWF molecules&nbsp;persist causing pathogenic platelet adhesion and aggregation. This causes&nbsp;localized<strong> platelet thrombi </strong>and<strong> fibrin deposits</strong>&nbsp;at various sites.</p>\n<p>It presents with the following pentad of clinical features:</p>\n<ol>\n<li>Microangiopathic <strong>hemolytic anemia</strong> -&nbsp;mechanical shearing of RBCs as they pass through platelet rich-microthrombi</li>\n<li>Thrombocytopenia -&nbsp;deposition of platelets in microthrombi</li>\n<li><strong>Renal failure</strong> -&nbsp;microthrombi in the renal vasculature</li>\n<li>Neurologic findings -&nbsp;headache, confusion, transient <strong>focal neurologic deficits</strong></li>\n<li>Fever</li>\n</ol><hr><h3>Related Pearl: Differences between TTP and HUS</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>TTP</strong></p>\n</td>\n<td>\n<p><strong>HUS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Causative agent</p>\n</td>\n<td>\n<p>A deficiency of, or antibodies to the metalloprotease ADAMTS13</p>\n</td>\n<td>\n<p>E. coli (O157: H7)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GI prodrome</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Age group affected</p>\n</td>\n<td>\n<p>Adults</p>\n</td>\n<td>\n<p>Children</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex affected</p>\n</td>\n<td>\n<p>Females</p>\n</td>\n<td>\n<p>No sex predilection</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Relapses</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Renal impairment</p>\n</td>\n<td>\n<p>Usually mild</p>\n</td>\n<td>\n<p>Often severe</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Severe thrombocytopenia</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Pentad of TTP and triad of HUS</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f1004c9ccec548288509c1eaed783d3fx1280x1840.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4070",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is incorrect regarding patients with thrombotic thrombocytopenic purpura?",
      "choices": [
        {
          "id": 1,
          "text": "Clinical features overlap with hemolytic uremic syndrome"
        },
        {
          "id": 2,
          "text": "PT and aPTT are prolonged"
        },
        {
          "id": 3,
          "text": "It is common in patients with HIV infection"
        },
        {
          "id": 4,
          "text": "It can be associated with use of quinine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In patients with thrombotic thrombocytopenic purpura (<strong>TTP</strong>), the <strong>PT</strong> and <strong>aPTT</strong> are <strong>normal</strong>, as consumptive coagulopathy is not seen.</p>\n<p>TTP and <strong>HUS</strong> are thrombotic microangiopathies with overlapping clinical features. TTP can be primary (ADAMTS13 deficiency) or secondary (associated with infections like <strong>HIV</strong> and drugs like <strong>quinine</strong>).</p>\n<p>Note: In disseminated intravascular coagulation (<strong>DIC</strong>),&nbsp;thrombocytopenia and microangiopathy are seen. It is associated with consumption of clotting factors and fibrinogen resulting in prolonged PT and aPTT.</p><hr><h3>Related Pearl: Differences between TTP and HUS</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Features</strong></p>\n</td>\n<td>\n<p><strong>TTP</strong></p>\n</td>\n<td>\n<p><strong>HUS</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Causative agent</p>\n</td>\n<td>\n<p>A deficiency of, or antibodies to the metalloprotease ADAMTS13</p>\n</td>\n<td>\n<p>E. coli (O157: H7)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GI prodrome</p>\n</td>\n<td>\n<p>Uncommon</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Age group affected</p>\n</td>\n<td>\n<p>Adults</p>\n</td>\n<td>\n<p>Children</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sex affected</p>\n</td>\n<td>\n<p>Females</p>\n</td>\n<td>\n<p>No sex predilection</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Relapses</p>\n</td>\n<td>\n<p>Common</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Renal impairment</p>\n</td>\n<td>\n<p>Usually mild</p>\n</td>\n<td>\n<p>Often severe</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Severe thrombocytopenia</p>\n</td>\n<td>\n<p>Often</p>\n</td>\n<td>\n<p>Rare</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Pentad of TTP and triad of HUS</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f1004c9ccec548288509c1eaed783d3fx1280x1840.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4071",
      "difficulty": "easy"
    },
    {
      "text": "What is the most common genetic abnormality seen in patients with recurrent history of venous thrombosis?",
      "choices": [
        {
          "id": 1,
          "text": "Factor V Leiden mutation"
        },
        {
          "id": 2,
          "text": "Prothrombin mutation"
        },
        {
          "id": 3,
          "text": "Protein C deficiency"
        },
        {
          "id": 4,
          "text": "Antithrombin III deficiency"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Factor V Leiden</strong> mutation is the most common <strong>inherited</strong> cause of venous thrombosis.&nbsp;Venous thrombosis typically manifests as deep vein thrombosis and pulmonary thromboembolism.&nbsp;</p>\n<p>Hypercoagulable states or thrombophilias can be inherited or acquired:</p>\n<ul>\n<li><strong>Inherited causes</strong>&nbsp;in decreasing order of prevalence are as follows:\n<ul>\n<li>Factor V Leiden mutation</li>\n<li>Prothrombin mutation</li>\n<li>Protein C deficiency</li>\n<li>Protein S deficiency</li>\n<li>Antithrombin III deficiency</li>\n</ul>\n</li>\n<li><strong>Acquired causes</strong>&nbsp;include:\n<ul>\n<li>Surgery</li>\n<li>Malignancy</li>\n<li>Antiphospholipid syndrome</li>\n<li>Trauma</li>\n<li>Pregnancy</li>\n<li>Long-haul travel</li>\n<li>Obesity</li>\n<li>Oral contraceptives/hormone replacement</li>\n<li>Myeloproliferative disorders</li>\n<li>Polycythemia vera</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1507",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following qualitative platelet disorders are inherited as autosomal dominant?",
      "choices": [
        {
          "id": 1,
          "text": "Glanzman thrombasthenia"
        },
        {
          "id": 2,
          "text": "Bernard Soulier syndrome"
        },
        {
          "id": 3,
          "text": "Chediak-Higashi syndrome"
        },
        {
          "id": 4,
          "text": "Platelet storage pool syndrome"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Platelet storage pool disease</strong> (SPD) is an example of an <strong>autosomal dominant</strong>&nbsp;qualitative platelet disorder.&nbsp;It refers to a group of disorders characterized by a deficiency of platelet granules causing secretion defects.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9d84bfdb468e467b9f06e8f391a6bf7ex1280x2203.JPEG\" alt=\"Explanation Image\"><p>Bernard Soulier syndrome,&nbsp;Glanzman thrombasthenia, and&nbsp;Chediak-Higashi syndrome are inherited as<strong> autosomal recessive</strong> traits.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4075",
      "difficulty": "hard"
    }
  ]
}